Kenneth D Setchell

US Patent:

20040235758, Nov 25, 2004

Filed:

Jul 24, 2003

Appl. No.:

10/625934

Inventors:

Kenneth Setchell - Cincinnati OH, US
Sidney Cole - Port Macquarie, AU

International Classification:

A61K031/7048
A61K031/353

US Classification:

514/027000, 514/456000

Abstract:

A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.

US Patent:

20050245492, Nov 3, 2005

Filed:

Feb 17, 2005

Appl. No.:

11/059951

Inventors:

Edwin Lephart - Orem UT, US
Trent Lund - Wheaton IL, US
Kenneth Reginald Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US

International Classification:

A61K031/56

US Classification:

514170000

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

US Patent:

20060122262, Jun 8, 2006

Filed:

Oct 29, 2003

Appl. No.:

10/533045

Inventors:

Edwin Lephart - Orem UT, US
Trent Lund - Wheaton IL, US
Kenneth David Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US

International Classification:

A61K 31/353

US Classification:

514456000

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

US Patent:

20070027329, Feb 1, 2007

Filed:

Aug 1, 2005

Appl. No.:

11/194280

Inventors:

Kenneth Setchell - Cincinnati OH, US
Victor Sorokin - Cincinnati OH, US

International Classification:

C07D 311/02

US Classification:

549402000

Abstract:

A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.

US Patent:

20070043108, Feb 22, 2007

Filed:

Aug 18, 2006

Appl. No.:

11/506443

Inventors:

Edwin Lephart - Orem UT, US
Trent Lund - St. Charles IL, US
Kenneth Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US

International Classification:

A61K 31/353

US Classification:

514456000

Abstract:

The invention is directed to a method of preventing or ameliorating a neuropsychiatric or neurodegenerative disease or disorder in a subject. The method includes administering a composition comprising equol in an amount sufficient to prevent or ameliorate the neuropsychiatric or neurodegenerative disease or disorder. The equol may be a racemic mixture of R-equol and S-equol. The equol may be enantiomerically enriched with R-equol or enantiomerically enriched with Sequol.

US Patent:

20120122967, May 17, 2012

Filed:

Jul 24, 2003

Appl. No.:

10/625989

Inventors:

Kenneth SETCHELL - Cincinnati OH, US
Sidney COLE - Port Macquarie, NSW, AU

Assignee:

AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITED - NSW
CHILDREN'S HOSPITAL MEDICAL CENTER - Cincinnati OH

International Classification:

A61K 31/7048
A61K 47/00
A61K 31/353

US Classification:

514456000, 514027000, 424439000

Abstract:

A composition for use in making commercial food and skin products comprising R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering R-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The R-equol enantiomer can be produced by chiral-phase column separation from a racemic mixture of equol.

US Patent:

20220205982, Jun 30, 2022

Filed:

May 15, 2020

Appl. No.:

17/611398

Inventors:

- Cincinnati OH, US
Kenneth D.R. SETCHELL - Cincinnati OH, US
Alexander A. VINKS - Cincinnati OH, US

Assignee:

CHILDREN'S HOSPITAL MEDICAL CENTER - Cincinnati OH

International Classification:

G01N 33/50
A61K 31/198
A61K 39/395
A61K 31/7076
A61K 35/28
A61P 37/06

Abstract:

A method for determining a personalized full dose of a melphalan compound (e.g., melphalan) in a reduced intensity conditioning regimen (RIC) prior to hematopoietic cell transplantation for a subject based on pharmacokinetic features of the melphalan compound administered to the subject at a test dose.

US Patent:

20170100462, Apr 13, 2017

Filed:

Nov 22, 2016

Appl. No.:

15/358620

Inventors:

- Cincinnati OH, US
Kenneth D.R. Setchell - Cincinnati OH, US
Lindsey Romick-Rosendale - Cincinnati OH, US
Wujuan Zhang - Cincinnati OH, US
Xueheng Zhao - Cincinnati OH, US

International Classification:

A61K 38/46
A61K 47/26
C12N 15/113
A61K 31/445
A61K 31/451

Abstract:

Markers for genomic instability in Fanconi Anemia (FA) and other pathologies for therapeutic and diagnostic uses. In one embodiment, glycosphingolipid metabolism is altered in the FA deficient squamous cell carcinoma (SCC) cells, based on analysis of a metabolomics/lipidomics platform. The data indicated ganglioside metabolism was important in FA patients' susceptibility to SCC progression.